# Contents

**Perspectives**

A Novel Look into Estrogen Receptor–Negative Breast Cancer Prevention with the Natural, Multifunctional Signal Transduction Inhibitor Deguelin. Jennifer M. Rodenberg and Powel H. Brown ................................................................. 915

*Perspective on Murillo et al., p. 942*

Oral Cancer Prevention Advances with a Translational Trial of Green Tea. Dong M. Shin ............... 919

*Perspective on Tsao et al., p. 931*

**Review**


**Research Articles**


Deguelin Inhibits Growth of Breast Cancer Cells by Modulating the Expression of Key Members of the Wnt Signaling Pathway. Genoveva Murillo, Xinjian Peng, Karen E.O. Torres, and Rajendra G. Mehta ............................................................................................................. 942


Effect of Orally Administered Bovine Lactoferrin on the Growth of Adenomatous Colorectal Polyps in a Randomized, Placebo-Controlled Clinical Trial. Takahiro Kozu, Gen Inunuma, Yasuo Ohashi, Yutaka Saito, Takayuki Akasu, Daizo Saito, David B. Alexander, Masaaki Iigo, Tadao Kakizoe, and Hiroyuki Tsuda ......................................................................................................................... 975

Identification of Actively Translated mRNA Transcripts in a Rat Model of Early-Stage Colon Carcinogenesis. Laurie A. Davidson, Naisyin Wang, Ivan Ivanov, Jennifer Goldsby, Joanne R. Lupton, and Robert S. Chapkin ......................................................................................................................... 984

**Meeting Report**

About the Cover
The cover figure depicts proposed mechanisms of action of the promising natural preventive agent deguelin. Previous work has demonstrated that deguelin inhibits the phosphatidylinositol 3-kinase (PI3K)/AKT and nuclear factor kappa B (NF-kB) signaling pathways in regulating gene expression (left side). Now, novel findings reported in this issue of the journal demonstrate that deguelin also regulates the Wnt/b-catenin pathway (right side) in ER-negative breast cancer cells. Deguelin inhibited both ER-positive and -negative breast-cancer cell growth, but most strongly in ER-negative cells, causing a cell-cycle blockade and inducing apoptosis. Deguelin joins only a small group of agents shown to inhibit the growth of ER-negative breast cancer cell lines. See articles by Murillo et al. (beginning on page 942) and Rodenberg and Brown (beginning on page 915) for more information.